Assistant Professor Mihai-Nelu Trofenciuc

Assistant Professor Mihai-Nelu Trofenciuc

Vasile Goldis Western University, Arad (Romania)

Member of:

Being a good doctor means being incredibly dedicated to what you and to love what you do. Sometimes it doesn't have to do with flights of intuition or brilliant diagnoses or even saving lives. It's all about dealing with a lot of people with chronic diseases that you really can't change or improve. You can help patients. You can make a difference in their lives, but you do that mostly by drudgery—day after day, paying attention to details, seeing patient after patient and complaint after complaint, and being responsive on the phone when you don't feel like being responsive

Presentations

Association and prevalence of post-stroke erectile dysfunction with cardiovascular risk factors and co-morbidities

Event: ESC Congress 2019

Topic: Neurologic Disorders and Heart Disease

Session: Neurologic disorders and heart disease

Access

T2* for Doxorubicin induced cardiotoxicity early assessment by septal myocardial iron levels determination

Event: EuroCMR 2019

Topic: T1 and T2 Mapping

Session: Poster session 2

Access

Cardiovascular rehabilitation before surgical revascularisation: short-term outcomes

Event: EuroPrevent 2019

Topic: Exercise Programmes

Session: Cardiovascular Rehabilitation and Exercise Testing

Access

One flight for a life - The pre-hospital emergency medicine (PHEM) aeromobile networking, can influence an acute coronary syndrome outcome?

Event: Acute Cardiovascular Care 2019

Topic: Prehospital and Emergency Department Care

Session: Acute Cardiac Care

Access

Cardiotoxicty ecocardioghaphic screening in HFpEF patients treated with doxorubicin

Event: EuroEcho-Imaging 2018

Topic: Echocardiography, Other

Session: Echocardiography, Other

Access

A non-biopsy genetic risk detection method from peripheral human blood for early detection of doxorubicin induced cardiotoxicity

Event: Heart Failure 2018

Topic: Cardiotoxicity of Drugs and Other Therapies

Session: Chronic Heart Failure – Pathophysiology and Mechanisms

Access

Anthracycline cardiotoxicity 2.4 or Toll-Like Receptor root of all evil

Event: Frontiers in CardioVascular Biology 2018

Topic: Biomarkers

Session: Basic Science - Cardiac Diseases

Access

Laboratory TLR4 and TLR2 detection method from peripheral human blood for early detection of doxorubicin induced cardiotoxicity

Event: ESC Congress 2017

Topic: Cardiotoxicity of drugs

Session: Chronic heart failure (CHF)

Access

Cost-effectiveness for risk factor determination and management of cardiac magnetic resonance vs. predictive tlr2/tlr4 genetic tests for early anthracycline-induced cardiotoxicity

Event: EuroCMR 2017

Topic: Cardiac Magnetic Resonance

Session: Quick Fire abstract session 5

Access

Customized laboratory TLR4 and TLR2 detection method from peripheral human blood for early detection of doxorubicin induced cardiotoxicity

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Topic: Cancer/Cardiotoxicity

Session: Basic science - Translational biomarkers and cardio-renal syndrome

Access

ESC 365 is supported by

Explore sponsored resources

Assistant Professor Mihai-Nelu Trofenciuc

Biography

Contributor content

Association and prevalence of post-stroke erectile dysfunction with cardiovascular risk factors and co-morbidities

T2* for Doxorubicin induced cardiotoxicity early assessment by septal myocardial iron levels determination

Cardiovascular rehabilitation before surgical revascularisation: short-term outcomes

One flight for a life - The pre-hospital emergency medicine (PHEM) aeromobile networking, can influence an acute coronary syndrome outcome?

Cardiotoxicty ecocardioghaphic screening in HFpEF patients treated with doxorubicin

A non-biopsy genetic risk detection method from peripheral human blood for early detection of doxorubicin induced cardiotoxicity

Anthracycline cardiotoxicity 2.4 or Toll-Like Receptor root of all evil

Laboratory TLR4 and TLR2 detection method from peripheral human blood for early detection of doxorubicin induced cardiotoxicity

Cost-effectiveness for risk factor determination and management of cardiac magnetic resonance vs. predictive tlr2/tlr4 genetic tests for early anthracycline-induced cardiotoxicity

Customized laboratory TLR4 and TLR2 detection method from peripheral human blood for early detection of doxorubicin induced cardiotoxicity

ESC 365 is supported by

Assistant Professor Mihai-Nelu Trofenciuc Follow

Biography

Contributor content

Association and prevalence of post-stroke erectile dysfunction with cardiovascular risk factors and co-morbidities

T2* for Doxorubicin induced cardiotoxicity early assessment by septal myocardial iron levels determination

Cardiovascular rehabilitation before surgical revascularisation: short-term outcomes

One flight for a life - The pre-hospital emergency medicine (PHEM) aeromobile networking, can influence an acute coronary syndrome outcome?

Cardiotoxicty ecocardioghaphic screening in HFpEF patients treated with doxorubicin

A non-biopsy genetic risk detection method from peripheral human blood for early detection of doxorubicin induced cardiotoxicity

Anthracycline cardiotoxicity 2.4 or Toll-Like Receptor root of all evil

Laboratory TLR4 and TLR2 detection method from peripheral human blood for early detection of doxorubicin induced cardiotoxicity

Cost-effectiveness for risk factor determination and management of cardiac magnetic resonance vs. predictive tlr2/tlr4 genetic tests for early anthracycline-induced cardiotoxicity

Customized laboratory TLR4 and TLR2 detection method from peripheral human blood for early detection of doxorubicin induced cardiotoxicity

ESC 365 is supported by

Assistant Professor Mihai-Nelu Trofenciuc